Retatrutide, by Soma Corp., is receiving significant attention as a innovative therapy for obesity control . This unique medication combines the activity of a GLP-1 receptor stimulant and a GIP receptor agonist , designed to not only promote metabolic improvements but also target underlying metabolic conditions . Preliminary human trials have indic